Rescue of human RET gene expression by sodium butyrate: A novel powerful tool for molecular studies in hirschsprung disease

P. Griseri, G. Patrone, F. Puppo, G. Romeo, R. Ravazzolo, I. Ceccherini

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Background: The RET gene encodes a tyrosine kinase receptor involved in different human neurocristopathies, such as specific neuroendocrine tumours and Hirschsprung disease (HSCR). Gene expression is developmentally regulated and the RET transcript is undetectable in most adult cells, including lymphocytes. The impossibility of performing functional studies on RET mRNA has to date limited the detection and characterisation of an indefinite proportion of gene anomalies that cannot be identified by conventional DNA genomic screening in HSCR cases. Aims: Development of a protocol suitable to activate RET expression in RET negative cell lines and therefore to investigate directly RET mRNA, extending the conventional gene mutation analysis to detection of splicing anomalies and impaired expression of the RET gene. Methods: The effect of sodium butyrate (NaB), a histone deacetylase inhibitor, on rescuing RET expression was tested by one round of reverse transcription- polymerase chain reaction from total RNA of treated lymphoblasts from both HSCR patients and control individuals. Results: Analysis of RET expression was possible by NaB treatment of RET negative cells, such as lymphoblasts. This treatment allowed us to detect impaired RET expression as well as a splicing defect in two HSCR patients previously believed to be devoid of any gene abnormality. Conclusions: The full application of the proposed protocol in most of the unexplained HSCR cases will allow us to establish the precise role of RET not only in causing but also in predisposing to HSCR pathogenesis.

Original languageEnglish
Pages (from-to)1154-1158
Number of pages5
JournalGut
Volume52
Issue number8
DOIs
Publication statusPublished - Aug 1 2003

Fingerprint

Hirschsprung Disease
Butyric Acid
Gene Expression
Genes
Messenger RNA
Histone Deacetylase Inhibitors
Neuroendocrine Tumors
Receptor Protein-Tyrosine Kinases
Reverse Transcription
Lymphocytes
RNA
Cell Line
Polymerase Chain Reaction
Mutation
DNA
Therapeutics

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Rescue of human RET gene expression by sodium butyrate : A novel powerful tool for molecular studies in hirschsprung disease. / Griseri, P.; Patrone, G.; Puppo, F.; Romeo, G.; Ravazzolo, R.; Ceccherini, I.

In: Gut, Vol. 52, No. 8, 01.08.2003, p. 1154-1158.

Research output: Contribution to journalArticle

@article{070217f88ee441139f355928083e6b96,
title = "Rescue of human RET gene expression by sodium butyrate: A novel powerful tool for molecular studies in hirschsprung disease",
abstract = "Background: The RET gene encodes a tyrosine kinase receptor involved in different human neurocristopathies, such as specific neuroendocrine tumours and Hirschsprung disease (HSCR). Gene expression is developmentally regulated and the RET transcript is undetectable in most adult cells, including lymphocytes. The impossibility of performing functional studies on RET mRNA has to date limited the detection and characterisation of an indefinite proportion of gene anomalies that cannot be identified by conventional DNA genomic screening in HSCR cases. Aims: Development of a protocol suitable to activate RET expression in RET negative cell lines and therefore to investigate directly RET mRNA, extending the conventional gene mutation analysis to detection of splicing anomalies and impaired expression of the RET gene. Methods: The effect of sodium butyrate (NaB), a histone deacetylase inhibitor, on rescuing RET expression was tested by one round of reverse transcription- polymerase chain reaction from total RNA of treated lymphoblasts from both HSCR patients and control individuals. Results: Analysis of RET expression was possible by NaB treatment of RET negative cells, such as lymphoblasts. This treatment allowed us to detect impaired RET expression as well as a splicing defect in two HSCR patients previously believed to be devoid of any gene abnormality. Conclusions: The full application of the proposed protocol in most of the unexplained HSCR cases will allow us to establish the precise role of RET not only in causing but also in predisposing to HSCR pathogenesis.",
author = "P. Griseri and G. Patrone and F. Puppo and G. Romeo and R. Ravazzolo and I. Ceccherini",
year = "2003",
month = "8",
day = "1",
doi = "10.1136/gut.52.8.1154",
language = "English",
volume = "52",
pages = "1154--1158",
journal = "Gut",
issn = "0017-5749",
publisher = "BMJ Publishing Group",
number = "8",

}

TY - JOUR

T1 - Rescue of human RET gene expression by sodium butyrate

T2 - A novel powerful tool for molecular studies in hirschsprung disease

AU - Griseri, P.

AU - Patrone, G.

AU - Puppo, F.

AU - Romeo, G.

AU - Ravazzolo, R.

AU - Ceccherini, I.

PY - 2003/8/1

Y1 - 2003/8/1

N2 - Background: The RET gene encodes a tyrosine kinase receptor involved in different human neurocristopathies, such as specific neuroendocrine tumours and Hirschsprung disease (HSCR). Gene expression is developmentally regulated and the RET transcript is undetectable in most adult cells, including lymphocytes. The impossibility of performing functional studies on RET mRNA has to date limited the detection and characterisation of an indefinite proportion of gene anomalies that cannot be identified by conventional DNA genomic screening in HSCR cases. Aims: Development of a protocol suitable to activate RET expression in RET negative cell lines and therefore to investigate directly RET mRNA, extending the conventional gene mutation analysis to detection of splicing anomalies and impaired expression of the RET gene. Methods: The effect of sodium butyrate (NaB), a histone deacetylase inhibitor, on rescuing RET expression was tested by one round of reverse transcription- polymerase chain reaction from total RNA of treated lymphoblasts from both HSCR patients and control individuals. Results: Analysis of RET expression was possible by NaB treatment of RET negative cells, such as lymphoblasts. This treatment allowed us to detect impaired RET expression as well as a splicing defect in two HSCR patients previously believed to be devoid of any gene abnormality. Conclusions: The full application of the proposed protocol in most of the unexplained HSCR cases will allow us to establish the precise role of RET not only in causing but also in predisposing to HSCR pathogenesis.

AB - Background: The RET gene encodes a tyrosine kinase receptor involved in different human neurocristopathies, such as specific neuroendocrine tumours and Hirschsprung disease (HSCR). Gene expression is developmentally regulated and the RET transcript is undetectable in most adult cells, including lymphocytes. The impossibility of performing functional studies on RET mRNA has to date limited the detection and characterisation of an indefinite proportion of gene anomalies that cannot be identified by conventional DNA genomic screening in HSCR cases. Aims: Development of a protocol suitable to activate RET expression in RET negative cell lines and therefore to investigate directly RET mRNA, extending the conventional gene mutation analysis to detection of splicing anomalies and impaired expression of the RET gene. Methods: The effect of sodium butyrate (NaB), a histone deacetylase inhibitor, on rescuing RET expression was tested by one round of reverse transcription- polymerase chain reaction from total RNA of treated lymphoblasts from both HSCR patients and control individuals. Results: Analysis of RET expression was possible by NaB treatment of RET negative cells, such as lymphoblasts. This treatment allowed us to detect impaired RET expression as well as a splicing defect in two HSCR patients previously believed to be devoid of any gene abnormality. Conclusions: The full application of the proposed protocol in most of the unexplained HSCR cases will allow us to establish the precise role of RET not only in causing but also in predisposing to HSCR pathogenesis.

UR - http://www.scopus.com/inward/record.url?scp=0037622910&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037622910&partnerID=8YFLogxK

U2 - 10.1136/gut.52.8.1154

DO - 10.1136/gut.52.8.1154

M3 - Article

C2 - 12865274

AN - SCOPUS:0037622910

VL - 52

SP - 1154

EP - 1158

JO - Gut

JF - Gut

SN - 0017-5749

IS - 8

ER -